These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29763659)

  • 1. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
    Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
    Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
    Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
    Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
    Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
    Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults.
    Dorinsky P; DePetrillo P; DeAngelis K; Trivedi R; Darken P; Gillen M
    Clin Ther; 2020 Apr; 42(4):634-648. PubMed ID: 32253054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
    Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults.
    Maes A; DePetrillo P; Siddiqui S; Reisner C; Dorinsky P
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):223-233. PubMed ID: 29901860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Reisner C; Dorinsky P
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2993-3002. PubMed ID: 31920296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.
    Huang Y; Assam PN; Feng C; Su R; Dorinsky P; Gillen M
    Pulm Pharmacol Ther; 2020 Oct; 64():101976. PubMed ID: 33152467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study.
    Kerwin EM; Ferguson GT; Mo M; DeAngelis K; Dorinsky P
    Respir Res; 2019 Jul; 20(1):167. PubMed ID: 31358008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
    van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
    Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.
    Aurivillius M; Bednarczyk A; Kokot M; Madriaga J; Mei J; Collison K; Surujbally R; Archbell J; Joshi V; Gillen M
    Pulm Pharmacol Ther; 2023 Dec; 83():102245. PubMed ID: 37607661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.